Washington University School of Medicine: Leukemia, Myeloid, Acute trials

The registry lists 38 Leukemia, Myeloid, Acute studies with Washington University School of Medicine as lead sponsor. 4 are open to participants now and 18 have results posted.

Early Phase 1 1Phase 1 23Phase 2 22No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNot yet recruitingNCT07617363Phase 1
• Motixafortide for MRD Sensitization in AMLRecruitingNCT07392970Phase 2
• Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AMLRecruitingNCT06158828Phase 1/2
• Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDSRecruitingNCT04986657Not applicable
• Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)TerminatedNCT04582864Phase 2Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell TransplantCompletedNCT03068819Phase 1/2Results posted
• Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03063203Phase 2Results posted
• Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell TransplantationActive, not recruitingNCT02782546Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02416908Phase 1/2Results posted
• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT01898793Phase 1/2Results posted
• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell TransplantationTerminatedNCT01747499Phase 1/2Results posted
• Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01687400Phase 2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• Azacitidine and Lenalidomide for Acute Myeloid LeukemiaCompletedNCT01016600Phase 1/2Results posted
• Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid LeukemiaCompletedNCT00906945Phase 1/2Results posted
• LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)CompletedNCT00691938Phase 1/2Results posted
• Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic TransplantationTerminatedNCT00593645Phase 2Results posted
• Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q AbnormalitiesCompletedNCT00546897Phase 2Results posted
• AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid LeukemiaCompletedNCT00512252Phase 1/2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 1
• Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDSWithdrawnNCT04893915Phase 2
• Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AMLWithdrawnNCT04354025Phase 2
• AML/MDS Drug Sensitization by in Vivo Chemotherapy AdministrationActive, not recruitingNCT04263181
• CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
• Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation ClearanceActive, not recruitingNCT02756962Phase 2
• Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
• Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02057770Phase 1
• Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
• Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell TransplantCompletedNCT01390311Phase 1
• Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AMLCompletedNCT01161550Phase 1
• IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)TerminatedNCT01027923Phase 1
• Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)CompletedNCT01001143Phase 1
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
• Oral Clofarabine for Acute Myeloid LeukemiaCompletedNCT00727766Phase 1
• Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1